title: Effect of single-dose administration of recombinant interferon-alpha2b on gastric myoelectrical activity in patients with chronic hepatitis C.
abstract: BACKGROUND
  Upper abdominal complaints during interferon therapy may result from impaired gastric motility and/or evacuatory function. We examined the effect of acute administration of interferon on gastric myoelectrical activity (GMA) with the use of surface electrogastrography.
  
  
  METHODS
  The study population comprised 25 patients with chronic hepatitis C. All of them were naive to interferon. On 2 days, after a 25-min basal GMA registration, in group A (5 men, 7 women, aged 44.3 +/- 2.8 years) placebo or 5 million i.u. recombinant interferon alpha-2b (IFNA) was administered s.c. and the GMA was recorded in the interdigestive state for two periods (2 h and 4 h), separated by a 15-min break. In group B (7 men, 6 women, aged 44.7 +/- 3.9 years) placebo or 5 million i.u. IFNA was injected s.c. after the ingestion of a semiliquid test meal of 364 kcal. Subsequently, the postprandial GMA was recorded for two periods (2 h and 4 h), separated by a 15-min break.
  
  
  RESULTS
  A typical flu-like syndrome was observed in 91.7% of patients in group A, and in 92.3% of patients in group B, thus providing evidence of the pharmacodynamic efficiency of the IFNA administration. In the fasted state, IFNA brought about a negligible increase in the rhythmicity and power of the gastric slow waves. IFNA did not elicit any statistically significant effect on gastric slow-wave activity postprandially.
  
  
  CONCLUSIONS
  Acute administration of interferon does not involve any deterioration of GMA that could be linked to the previously reported upper abdominal symptoms in patients undergoing treatment with this drug.
authors.affiliation: Department of Basic Biomedical Science, School of Pharmacy, Medical University of Silesia, 3, Kasztanowa Street, PL-41-205, Sosnowiec, Poland.
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Jonderko
authors.forename: Beata
authors.initials: B
authors.lastname: Krusiec-Swidergoł
authors.forename: Włodzimierz
authors.initials: W
authors.lastname: Mazur
authors.forename: Anna
authors.initials: A
authors.lastname: Kasicka-Jonderko
authors.forename: Maciej
authors.initials: M
authors.lastname: Gonciarz
authors.forename: Barbara
authors.initials: B
authors.lastname: Błońska-Fajfrowska
authors.forename: Zbigniew
authors.initials: Z
authors.lastname: Gonciarz
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D004311:Double-Blind Method; D004576:Electromyography; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D016065:Myoelectric Complex, Migrating / Q000187:drug effects*; D011994:Recombinant Proteins; D013270:Stomach / Q000294:innervation / Q000502:physiology*
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins